CONNECT WITH US
HealthTech

HealthTech

New targeted therapy improved survival for patients with KRAS-mutated lung cancer

Medical Xpress logo

Published on

Add as a preferred source on Google
New targeted therapy improved survival for patients with KRAS-mutated lung cancer

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

Patients with previously treated advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC) lived significantly longer and saw improved disease control when treated with the next-generation KRAS-targeted therapy divarasib, according to researchers from The University of Texas MD Anderson Cancer Center.

Results from the global Phase III Krascendo 1 study were published in The New England Journal of Medicine and presented at the European Society for Medical Oncology (ESMO) Congress 2026. The study was led by principal investigator Ferdinandos Skoulidis, M.D., Ph.D., professor of Thoracic/Head and Neck Medical Oncology.

In the trial, researchers compared divarasib with two currently approved KRAS G12C inhibitors, sotorasib or adagrasib, in NSCLC patients whose cancer had progressed after prior treatment. Treatment with divarasib reduced the risk of disease progression by 42% and the risk of death by 44%. Median overall survival improved with divarasib to 17.7 months versus 12 months with sotorasib/adagrasib.

"For patients with KRAS G12C-mutant lung cancer, extending survival and delaying cancer progression are the outcomes that matter most," Skoulidis said. "Divarasib significantly improved both measures compared with currently available KRAS inhibitors. These results establish divarasib as a new standard of care and offer hope for patients whose treatment options have been limited after their cancer progresses."

KRAS is one of the most commonly altered genes in NSCLC, and these mutations allow cancer cells to grow uncontrollably. Approximately 14% of patients with NSCLC have a specific type of mutation, known as KRAS G12C.


Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.